Cullinan Oncology reported a net loss of $25.6 million for the fourth quarter of 2023, with cash, cash equivalents, investments, and interest receivable totaling $468.3 million as of December 31, 2023. The company's cash resources are expected to provide runway into the second half of 2026. They also remain on track to report additional solid tumor dose escalation data for CLN-619 in Q2 2024 and received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma.